Oxford BioDynamics (LON:OBD) Hits New 52-Week Low – Should You Sell?

Shares of Oxford BioDynamics Plc (LON:OBD) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 0.45 ($0.01) and last traded at GBX 0.50 ($0.01), with a volume of 5137313 shares traded. The stock had previously closed at GBX 0.48 ($0.01).

Analysts Set New Price Targets

Separately, Shore Capital restated a “house stock” rating on shares of Oxford BioDynamics in a report on Thursday, March 13th.

Oxford BioDynamics Price Performance

The company has a market cap of £9.43 million, a P/E ratio of -0.09 and a beta of 0.42. The firm’s 50-day moving average is GBX 0.54 and its two-hundred day moving average is GBX 1.47. The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80.

Oxford BioDynamics (LON:OBD) last posted its earnings results on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) earnings per share for the quarter. Oxford BioDynamics had a negative return on equity of 289.38% and a negative net margin of 1,800.32%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.